Management of pulmonary arterial hypertension

Current Opinion in Critical Care

Volumn 19, Issue 1, 2013, Pages 44-50

  Judge, Eoin P ^a   Gaine, Sean P ^a  

^a MATER MISERICORDIAE UNIVERSITY HOSPITAL   (Ireland)

Author keywords

lung transplantation; pulmonary arterial hypertension; pulmonary hypertension; registries; therapy

Indexed keywords

AMBRISENTAN; BOSENTAN; CALCIUM CHANNEL BLOCKING AGENT; DIGOXIN; DIURETIC AGENT; ENDOTHELIN RECEPTOR ANTAGONIST; ILOPROST; PHOSPHODIESTERASE V INHIBITOR; PROSTACYCLIN; PROSTANOID; SILDENAFIL; TADALAFIL; TREPROSTINIL;

ANTICOAGULATION; EXERCISE; HUMAN; LUNG CIRCULATION; LUNG TRANSPLANTATION; MONOTHERAPY; OXYGEN THERAPY; PULMONARY HYPERTENSION; REVIEW; TREATMENT OUTCOME;

ANTICOAGULANTS; ANTIHYPERTENSIVE AGENTS; COMBINED MODALITY THERAPY; DIURETICS; FEMALE; GUIDELINES AS TOPIC; HUMANS; HYPERBARIC OXYGENATION; HYPERTENSION, PULMONARY; MALE; OUTCOME ASSESSMENT (HEALTH CARE); PATIENT SELECTION; PHOSPHODIESTERASE 5 INHIBITORS; PROSTAGLANDINS; RECEPTORS, ENDOTHELIN; REGISTRIES;

EID: 84872177957     PISSN: 10705295     EISSN: 15317072     Source Type: Journal    
DOI: 10.1097/MCC.0b013e32835c5137     Document Type: Review

References (45)

1. Galie N, Hoeper MM, Humbert M, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: The Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J 2009; 30:2493-2537.
2. Simonneau G, Robbins IM, Beghetti M, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2009; 54 (1 Suppl):S43-S54.
3. Shapiro S, Traiger GL, Turner M, et al. Sex differences in the diagnosis, treatment, and outcome of patients with pulmonary arterial hypertension enrolled in the registry to evaluate early and long-term pulmonary arterial hypertension disease management. Chest 2012; 141:363-373.
4. McLaughlin VV, Archer SL, Badesch DB, et al. ACCF/AHA 2009 expert consensus document on pulmonary hypertension: A report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association: Developed in collaboration with the American College ofChest Physicians,American Thoracic Society, Inc., and the Pulmonary Hypertension Association. Circulation 2009; 119:2250-2294.
5. Jais X, Olsson KM, Barbera JA, et al. Pregnancy outcomes in pulmonary arterial hypertension in the modern management era. Eur Respir J 2012; 40:881-885.
6. Johnson SR, Granton JT, Tomlinson GA, et al. Warfarin in systemic sclerosisassociated and idiopathic pulmonary arterial hypertension. A Bayesian approach to evaluating treatment for uncommon disease. J Rheumatol 2012; 39:276-285.
7. Humbert M, Yaici A, de Groote P, et al. Screening for pulmonary arterial hypertension in patients with systemic sclerosis: Clinical characteristics at diagnosis and long-term survival. Arthritis Rheum 2011; 63:3522-3530.
8. Abud EM, Maylor J, Undem C, et al. Digoxin inhibits development of hypoxic pulmonary hypertension in mice. Proc Natl Acad Sci USA 2012; 109:1239-1244.
9. Grunig E, Lichtblau M, Ehlken N, et al. Safety and efficacy of exercise training in various forms of pulmonary hypertension. Eur Respir J 2012; 40:84-92.
10. Grunig E, Maier F, Ehlken N, et al. Exercise training in pulmonary arterial hypertension associated with connective tissue diseases. Arthritis Res Ther 2012; 14:R148.
11. Ley S, Fink C, Risse F, et al. Magnetic resonance imaging to assess the effect of exercise training on pulmonary perfusion and blood flow in patients with pulmonary hypertension. Eur Radiol 2012. [Epub ahead of print]
12. Zuo XR, Zhang R, Jiang X, et al. Usefulness of intravenous adenosine in idiopathic pulmonary arterial hypertension as a screening agent for identifying long-term responders to calcium channel blockers. Am J Cardiol 2012; 109:1801-1806.
13. Monfredi O, Griffiths L, Clarke B, Mahadevan VS. Efficacy and safety of bosentan for pulmonary arterial hypertension in adults with congenital heart disease. Am J Cardiol 2011; 108:1483-1488.
14. Kaya MG, Lam YY, Erer B, et al. Long-term effect of bosentan therapy on cardiac function and symptomatic benefits in adult patients with Eisenmenger syndrome. J Card Fail 2012; 18:379-384.
15. Savale L, Magnier R, Le Pavec J, et al. Efficacy, safety, and pharmacokinetics of bosentan in portopulmonary hypertension. Eur Respir J 2012. [Epub ahead of print]
16. Badesch DB, Feldman J, Keogh A, et al. ARIES-3: Ambrisentan therapy in a diverse population of patients with pulmonary hypertension. Cardiovasc Ther 2012; 30:93-99.
17. D'Alto M, Romeo E, Argiento P, et al. Ambrisentan for pulmonary arterial hypertension: Long term effects on clinical status, exercise capacity and haemodynamics. Int J Cardiol 2012; 156:244-245.
18. Klinger JR, Oudiz RJ, Spence R, et al. Long-term pulmonary hemodynamic effects of ambrisentan in pulmonary arterial hypertension. Am J Cardiol 2011; 108:302-307.
19. Gabler NB, French B, Strom BL, et al. Race and sex differences in response to endothelin receptor antagonists for pulmonary arterial hypertension. Chest 2012; 141:20-26.
20. Shapiro S, Pollock DM, Gillies H, et al. Frequency of edema in patients with pulmonary arterial hypertension receiving ambrisentan. Am J Cardiol 2012; 110:1373-1377.
21. Ben-Yehuda O, Pizzuti D, Brown A, et al. Long-term hepatic safety of ambrisentan in patients with pulmonary arterial hypertension. J Am Coll Cardiol 2012; 60:80-81.
22. Rubin LJ, Badesch DB, Fleming TR, et al. Long-term treatment with sildenafil citrate in pulmonary arterial hypertension: The SUPER-2 study. Chest 2011; 140:1274-1283.
23. Oudiz RJ, Brundage BH, Galie N, et al. Tadalafil for the treatment of pulmonary arterial hypertension: A double-blind 52-week uncontrolled extension study. J Am Coll Cardiol 2012; 60:768-774.
24. Jing ZC, Yu ZX, Shen JY, et al. Vardenafil in pulmonary arterial hypertension: A randomized, double-blind, placebo-controlled study. Am J Respir Crit Care Med 2011; 183:1723-1729.
25. Shlobin OA, Whitney Brown A, Weir N, et al. Transition of PH patients from sildenafil to tadalafil: Feasibility and practical considerations. Lung 2012; 190:573-578.
26. Barst RJ, Rubin LJ, Long WA, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group. N Engl J Med 1996; 334:296-302.
27. Higenbottam T, Butt AY, McMahon A, et al. Long-term intravenous prostaglandin (epoprostenol or iloprost) for treatment of severe pulmonary hypertension. Heart 1998; 80:151-155. (Pubitemid 28389476)
28. Olschewski H, Simonneau G, Galie N, et al. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med 2002; 347:322-329. (Pubitemid 34815354)
29. Sadushi-Kolici R, Skoro-Sajer N, Zimmer D, et al. Long-term treatment, tolerability, and survival with sub-cutaneous treprostinil for severe pulmonary hypertension. J Heart Lung Transplant 2012; 31:735-743.
30. Kitterman N, Poms A, Miller DP, et al. Bloodstream infections in patients with pulmonary arterial hypertension treated with intravenous prostanoids: Insights from the REVEAL REGISTRY((R)). Mayo Clin Proc 2012; 87:825-834.
31. Perez VA, Rosenzweig E, Rubin LJ, et al. Safety and efficacy of transition from systemic prostanoids to inhaled treprostinil in pulmonary arterial hypertension. Am J Cardiol 2012; 110:1546-1550.
32. Bourge RC, Tapson VF, Safdar Z, et al. Rapid transition from inhaled iloprost to inhaled treprostinil in patients with pulmonary arterial hypertension. Cardiovasc Ther 2012. [Epub ahead of print]
33. Simonneau G, Rubin LJ, Galie N, et al. Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: A randomized trial. Ann Intern Med 2008; 149:521-530.
34. Benza RL, Seeger W, McLaughlin VV, et al. Long-term effects of inhaled treprostinil in patients with pulmonary arterial hypertension: The Treprostinil SodiumInhalation Used in the Management of Pulmonary Arterial Hypertension (TRIUMPH) study open-label extension. J Heart Lung Transplant 2011; 30:1327-1333.
35. Frantz RP, McDevitt S, Walker S. Baseline NT-proBNP correlates with change in 6-min walk distance in patients with pulmonary arterial hypertension in the pivotal inhaled treprostinil study TRIUMPH-1. J Heart Lung Transplant 2012; 31:811-816.
36. Kemp K, Savale L, O'Callaghan DS, et al. Usefulness of first-line combination therapy with epoprostenol and bosentan in pulmonary arterial hypertension: An observational study. J Heart Lung Transplant 2012; 31:150-158.
37. A study of first-line ambrisentan and tadalafil combination therapy in subjects with pulmonary arterial hypertension (PAH) (AMBITION). Available from: http://clinicaltrials.gov/ct2/show/NCT01178073.
38. Sandoval J, Gaspar J, Pena H, et al. Effect of atrial septostomy on the survival of patients with severe pulmonary arterial hypertension. Eur Respir J 2011; 38:1343-1348.
39. Christie JD, Edwards LB, Kucheryavaya AY, et al. The Registry of the InternationalSociety forHeart and Lung Transplantation:Twenty-eighthAdult Lung and Heart-Lung Transplant Report 2011. J Heart Lung Transplant 2011; 30:1104-1122.
40. McLaughlin VV. Looking to the future: A new decade of pulmonary arterial hypertension therapy. Eur Respir Rev 2011; 20:262-269.
41. Rubin L, Pulido T, Channick R, et al. Effect of macitentan on morbidity and mortality in pulmonary arterial hypertension (PAH): Results from the SERAPHIN trial. Chest 2012; 142 (4 Meeting Abstracts): 1026A.
42. Tapson VF, Torres F, Kermeen F, et al. Oral treprostinil for the treatment of pulmonary arterial hypertension in patients on background endothelin receptor antagonist and/or phosphodiesterase type 5 inhibitor therapy (The FREEDOM-C Study): A randomized controlled trial. Chest 2012. [Epub ahead of print]
43. McGoon MD, Miller DP. REVEAL: A contemporary US pulmonary arterial hypertension registry. Eur Respir Rev 2012; 21:8-18.
44. O'Callaghan DS, Humbert M. A critical analysis of survival in pulmonary arterial hypertension. Eur Respir Rev 2012; 21:218-222.
45. Humbert M, Sitbon O, Chaouat A, et al. Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era. Circulation 2010; 122:156-163.